New research from the University of Washington examines the behavior of prescription opioid companies following key events in Kentucky’s lawsuit against Purdue Pharma regarding its controlled-release oral formulation of oxycodone hydrochloride (OxyContin). While Purdue Pharma significantly decreased its marketing budget for OxyContin, the UW researchers found that Kentucky’s litigation had the opposite effect on competing companies, with those companies marketing opioids to physicians previously pursued by Purdue Pharma, including in counties where the opioid crisis was known to be severe….
UW research finds pharma companies increased opioids marketing after Purdue Pharma lawsuit









